TOOKAD Reduced Disease Worsening in Low-risk Prostate Cancer Patients After 4 Years, Study Found

TOOKAD Reduced Disease Worsening in Low-risk Prostate Cancer Patients After 4 Years, Study Found
Steba Biotech‘s TOOKAD treatment significantly reduces overall disease progression in men with low-risk prostate cancer, eliminating the need for most low-risk patients to undergo radical therapy, according to four-year follow-up data announced by the company. Results from the study, “Randomized Trial of Partial Gland Ablation with Vascular-Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer:

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. jimmy hodges says:

    i was daagnosed and biopsied 18 years ago,showed enlarged prostate,but negative for cancer,about 3 years ago another biopsy,it showed positive, the treatment suggested was wait and watch,this last biopsy being the only one since about 1997. my prostate number was 6. thank you very much, Jimmy

Leave a Comment

Your email address will not be published. Required fields are marked *